Clinical Context Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease worldwide, affecting approximately 40% of patients with type 2 diabetes. Despite advances in glucose and blood pressure control, many patients progress to kidney failure requiring dialysis or transplantation. Until recently, SGLT2 inhibitors were the only glucose-lowering agents proven to slow DKD progression in dedicated renal outcomes trials. The FLOW trial (Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes) represents a watershed moment in nephrology: the first dedicated renal outcomes trial of a GLP-1 receptor agonist. While previous cardiovascular outcomes trials (SUSTAIN-6,…
Author: FWA
Clinical Context Prediabetes affects approximately 96 million American adults—more than one-third of the adult population—and represents a critical window for diabetes prevention. Without intervention, 5-10% of individuals with prediabetes progress to type 2 diabetes annually, with up to 70% eventually developing the disease. Beyond diabetes risk, prediabetes itself is associated with increased cardiovascular disease, nephropathy, and neuropathy, making early intervention imperative. Landmark trials like the Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle intervention can reduce diabetes incidence by 58%, while metformin provides a more modest 31% reduction. However, sustaining lifestyle changes long-term remains challenging, and metformin’s effects are primarily…
Summary: In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide 2.4 mg for 52 weeks produced consistent weight reduction (-6.9% to -8.8%), greater symptom improvement in loop diuretic users (+9.3 vs +4.7 KCCQ points), and reduced loop diuretic doses by 17% compared to placebo (which showed 2.4% diuretic dose increase), with no significant safety signals across diuretic subgroups. PICO Description Population Adults with obesity-related HFpEF (BMI ≥30), pooled STEP-HFpEF trials (n=1,145), stratified by diuretic use. Intervention Semaglutide 2.4 mg subcutaneously once weekly for 52 weeks plus standard HFpEF care. Comparison…
In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
In adults with diabetes mellitus but no evident cardiovascular disease, aspirin at a dose of 100 mg daily significantly reduced the risk of serious vascular events by 12% compared to placebo, though it was associated with a 29% increased risk of major bleeding events.
Summary: In healthy Chinese adults (n=32), once-daily oral semaglutide escalated from 3 mg to 14 mg over 12 weeks demonstrated dose-dependent exposure (AUC, Cmax) comparable to global populations, with significant reductions in body weight (P=0.0001) and fasting glucose (P=0.0011) compared to matching placebo, with primarily GI adverse events (nausea, decreased appetite), no severe hypoglycemia or serious AEs. PICO Description Population Healthy Chinese adults (n=32), randomized to oral semaglutide or placebo. Intervention Once-daily oral semaglutide with dose escalation 3 mg → 7 mg → 14 mg over 12 weeks. Comparison Matching placebo under identical conditions (fasting, 30-min post-dose fasting). Outcome Dose-dependent…
Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and certain cancers. Beyond physical health, obesity significantly impacts quality of life, physical functioning, and psychological wellbeing. Traditional weight management approaches combining diet and exercise typically achieve modest weight loss of 3-5%, often insufficient to meaningfully improve health outcomes or quality of life. The STEP (Semaglutide Treatment Effect in People with obesity) program represents the largest clinical trial program for anti-obesity pharmacotherapy to date. These Phase 3 trials evaluated semaglutide 2.4 mg—a GLP-1 receptor agonist administered…
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular events has proven challenging. Previous weight loss interventions—whether through lifestyle modification, bariatric surgery, or medications—have struggled to demonstrate reduced cardiovascular mortality in randomized trials. This evidentiary gap led some to question whether obesity itself causes cardiovascular events or merely travels alongside other risk factors. The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) fundamentally changed this landscape. It was the first dedicated cardiovascular outcomes trial of an anti-obesity medication in patients without diabetes, and it…
Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median 3.4 years significantly reduced composite kidney endpoint (kidney failure, ≥50% eGFR decline, kidney death), slowed annual eGFR decline by 1.16 mL/min/1.73m², and reduced all-cause mortality by 20% compared to matching placebo, with fewer serious adverse events (49.6% vs 53.8%) and greater benefit in patients with baseline eGFR <60. PICO Description Population Adults with overweight/obesity (BMI ≥27) and established CVD, without diabetes, from SELECT trial. Intervention Semaglutide 2.4 mg subcutaneously once weekly for median 3.4 years. Comparison Matching placebo weekly for…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous weekly for 52 weeks significantly improved NYHA functional class (32.6% improved ≥1 class), with consistent KCCQ and physical function improvements across baseline NYHA categories compared to matching placebo, with similar weight reduction (~8%) regardless of baseline NYHA class and fewer patients experiencing deterioration. PICO Description Population 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%), NYHA class II-IV. Intervention Semaglutide 2.4 mg subcutaneous weekly for 52 weeks, titrated per standard protocol. Comparison Matching placebo weekly for 52 weeks, double-blind randomized.…